Evidence map›Paper›PMID 37382176›Full record

ArticleJournal of the American Heart Association2023

Eligibility for the 4 Pharmacological Pillars in Heart Failure With Reduced Ejection Fraction at Discharge.

Domenico D'Amario, Daniele Rodolico, Agni Delvinioti, Renzo Laborante, Chiara Iacomini, Carlotta Masciocchi, Attilio Restivo, Giuseppe Ciliberti, Mattia Galli, Antonio Donato Paglianiti and 7 more

Open access · goldAbstract read
In one paragraph

Article in Journal of the American Heart Association, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.

0numbers the graph read from it
0cells of the map it votes in
22citing papers in PubMed
7.0field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

22 citing papers in PubMed, 32 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Observational
  5. Article
  6. Article
  7. Review
  8. Article
  9. Review
  10. Advancing Cardiovascular, Kidney, and Metabolic Medicine: A Narrative Review of Insights and Innovations for the Future.Diabetes therapy : research, treatment and education of diabetes and related disorders · 2025
    Review
  11. Review
  12. Observational
  13. Impact of Heart Failure Team on Inpatient Rapid Sequencing of Heart Failure Therapy.Journal of cardiovascular development and disease · 2025
    Article
  14. Review
  15. Article
  16. Review
  17. Review
  18. Article
  19. Observational
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors at 3 institutions in 1 country.

Domenico D'AmarioDepartment of Translational Medicine Università del Piemonte Orientale Novara Italy.ORCID 0000-0003-3774-8330
Daniele RodolicoDepartment of Cardiovascular and Pulmonary Sciences Catholic University of the Sacred Heart Rome Italy.ORCID 0000-0003-4690-725X
Agni DelviniotiFondazione Policlinico Universitario A. Gemelli IRCCS Rome Italy.ORCID 0000-0002-2402-9444
Renzo LaboranteDepartment of Cardiovascular and Pulmonary Sciences Catholic University of the Sacred Heart Rome Italy.ORCID 0009-0006-1587-831X
Chiara IacominiFondazione Policlinico Universitario A. Gemelli IRCCS Rome Italy.ORCID 0000-0001-7701-1929
Carlotta MasciocchiFondazione Policlinico Universitario A. Gemelli IRCCS Rome Italy.ORCID 0000-0001-6415-7267
Attilio RestivoDepartment of Cardiovascular and Pulmonary Sciences Catholic University of the Sacred Heart Rome Italy.ORCID 0000-0002-9097-5287
Giuseppe CilibertiDepartment of Cardiovascular and Pulmonary Sciences Catholic University of the Sacred Heart Rome Italy.
Mattia GalliDepartment of Cardiovascular and Pulmonary Sciences Catholic University of the Sacred Heart Rome Italy.ORCID 0000-0003-3909-182X
Antonio Donato PaglianitiDepartment of Cardiovascular and Pulmonary Sciences Catholic University of the Sacred Heart Rome Italy.ORCID 0000-0003-2556-4809
Antonio IaconelliDepartment of Cardiovascular and Pulmonary Sciences Catholic University of the Sacred Heart Rome Italy.ORCID 0000-0001-7413-8449
Andrea ZitoDepartment of Cardiovascular and Pulmonary Sciences Catholic University of the Sacred Heart Rome Italy.ORCID 0000-0002-1351-6749
Jacopo LenkowiczFondazione Policlinico Universitario A. Gemelli IRCCS Rome Italy.
Stefano PatarnelloFondazione Policlinico Universitario A. Gemelli IRCCS Rome Italy.ORCID 0009-0008-2765-5935
Alfredo CesarioOpen Innovation Unit, Scientific Direction Fondazione Policlinico Universitario A. Gemelli IRCCS Rome Italy.ORCID 0000-0003-4687-0709
Vincenzo ValentiniDepartment of Bioimaging, Radiation Oncology and Hematology Fondazione Policlinico Universitario "A. Gemelli" IRCCS, Università Cattolica S. Cuore Rome Italy.ORCID 0000-0003-4637-6487
Filippo CreaDepartment of Cardiovascular and Pulmonary Sciences Catholic University of the Sacred Heart Rome Italy.ORCID 0000-0002-9482-411X
Università Cattolica del Sacro Cuore · ITAgostino Gemelli University Polyclinic · ITUniversità degli Studi del Piemonte Orientale “Amedeo Avogadro” · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background Guidelines recommend using multiple drugs in patients with heart failure (HF) with reduced ejection fraction, but there is a paucity of real-world data on the simultaneous initiation of the 4 pharmacological pillars at discharge after a decompensation event. Methods and Results A retrospective data mart, including patients diagnosed with HF, was implemented. Consecutively admitted patients with HF with reduced ejection fraction were selected through an automated approach and categorized according to the number/type of treatments prescribed at discharge. The prevalence of contraindications and cautions for HF with reduced ejection fraction treatments was systematically assessed. Logistic regression models were fitted to assess predictors of the number of treatments (≥2 versus <2 drugs) prescribed and the risk of rehospitalization. A population of 305 patients with a first episode of HF hospitalization and a diagnosis of HF with reduced ejection fraction (ejection fraction, <40%) was selected. At discharge, 49.2% received 2 current recommended drugs, β-blockers were prescribed in 93.4%, while a renin-angiotensin system inhibitor or an angiotensin receptor-neprilysin inhibitor was prescribed in 68.2%. A mineralocorticoid receptor antagonist was prescribed in 32.5%, although none of the patients showed contraindications to mineralocorticoid receptor antagonist prescription. A sodium-glucose cotransporter 2 inhibitor could be prescribed in 71.1% of patients. On the basis of current recommendations, 46.2% could receive the 4 foundational drugs at discharge. Renal dysfunction was associated with <2 foundational drugs prescribed. After adjusting for age and renal function, use of ≥2 drugs was associated with lower risk of rehospitalization during the 30 days after discharge. Conclusions A quadruple therapy could be directly implementable at discharge, potentially providing prognostic advantages. Renal dysfunction was the main prevalent condition limiting this approach.

Indexed as

Heart FailureKidney DiseasesVentricular Dysfunction, LeftAngiotensin Receptor AntagonistsAntihypertensive AgentsHumansMineralocorticoid Receptor AntagonistsPatient DischargeRetrospective StudiesStroke VolumeAngiotensin Receptor AntagonistsAntihypertensive AgentsMineralocorticoid Receptor Antagonists4 pillarscautionscomprehensive therapycontraindicationsheart failure with reduced ejection fraction

Identifiers

PMID37382176
PMCPMC10356099
OpenAlexW4382502187

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.